本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，海创药业股份有限公司（以下简称"公司"）从国家药品监督管理 局（以下简称"NMPA"）网站查询获悉，公司自主研发的 1 类新药海纳安®（通 用名：氘恩扎鲁胺软胶囊）获得国家药监局批准上市，用于治疗接受醋酸阿比 特龙及化疗后出现疾病进展，且既往未接受新型雄激素受体抑制剂的转移性去 势抵抗性前列腺癌（mCRPC）成人患者。根据公开资料查询，氘恩扎鲁胺软胶囊 是国内第一款针对该类患者人群获得批准上市的创新药物。 现将相关情况公告如下： 证券代码：688302 证券简称：海创药业 公告编号：2025-030 海创药业股份有限公司 自愿披露关于氘恩扎鲁胺软胶囊新药上市申请 获得批准的公告 氘恩扎鲁胺软胶囊（曾用名：HC-1119 软胶囊）是公司自主研发的、用于治 疗转移性去势抵抗性前列腺癌(mCRPC)的 1 类新药，是第二代雄激素受体（AR） 抑制剂，获得国家重大新药创制科技重大专项支持。氘恩扎鲁胺（HC-1119）中 国Ⅲ期临床研究达到主要终点，数据显示，相较 ...

Group 1 - The innovative drug concept stocks are experiencing a downturn, with several companies seeing declines of over 5% [1] - Notable companies affected include Sanofi, Haisun Pharmaceutical, Huisheng Biological, Rejing Biological, Haichuang Pharmaceutical, and Ruizhi Pharmaceutical [1] - Other companies such as Saiseng Pharmaceutical and Hasan Union are also following the downward trend [1]

证券代码：688302 证券简称：海创药业 公告编号：2025-029 海创药业股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 6 月 4 日（星期三）15:00-16:00 ? 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络文字互动 ? 投资者可于 2025 年 5 月 27 日（星期二）至 6 月 3 日（星期二） 公司邮箱 ir@hinovapharma.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 海创药业股份有限公司（以下简称"公司"）已于 2025 年 4 月 地了解公司 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 6 月 4 日（星期三）15:00-16:00 举行 2025 年第一季度业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会 ...

证券代码：688302 证券简称：海创药业 公告编号：2025-029 海创药业股份有限公司 重要内容提示： 投资者可于 2025 年 5 月 27 日（星期二）至 6 月 3 日（星期二） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 ir@hinovapharma.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 海创药业股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日发布公司 2025 年第一季度报告，为便于广大投资者更全面深入 地了解公司 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 6 月 4 日（星期三）15:00-16:00 举行 2025 年第一季度业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第一季度的经营成果及财务指标的具体情况与投资者进行互动交 会议召开时间：2025 年 6 月 4 日（星期三）15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： htt ...

智通财经5月21日电，舒泰神20CM涨停，此前三生国健3连板，赛升药业、海创药业、海辰药业、诺思 格、君实生物等跟涨。消息面上，港股创新药企三生制药公告称，其与辉瑞公司就前者自主研发的PD- 1/VEGF双特异性抗体SSGJ-707签订了独家许可协议。本次协议中12.5亿美元的首付款再次刷新了国产 创新药出海首付款金额纪录。 创新药概念延续强势 舒泰神20CM涨停 ...

关于海创药业股份有限公司 2024 年度持续督导跟踪报告 中信证券股份有限公司 一、持续督导工作情况 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场检查 的工作要求。 2、保荐人已与公司签订承销及保荐协议，该协议已明确了双方在持续督导期间 的权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、对上市公司培训等方式开 展持续督导工作，并于 2025 年 4 月 21 日至 4 月 24 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督导职 责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为海创 药业股份有限公司（以下简称"海创药业"或"公司"或"上市公司"）首次 公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续 督导职责，并出具本持续督导本年度跟踪报告。 （2）查阅公司内部审计和内控管理等内部控制制度，查阅了公司 2024 年度内 部控 ...

Group 1: 华峰化学 - Company decided to terminate the acquisition of 100% equity in Zhejiang Huafeng Synthetic Resin Co., Ltd. and Zhejiang Huafeng Thermoplastic Polyurethane Co., Ltd. due to insufficient shareholder approval [1] - The decision was made based on prudence, as the proposal did not receive more than two-thirds of the valid voting rights at the shareholders' meeting [1] - Company will continue to promote related equity injection work and strictly fulfill asset injection commitments [1] Group 2: 中荣股份 - Actual controller and chairman Huang Huanran has been placed under residential surveillance by the police [2] - Other board members and senior management are performing their duties normally, and the board of directors is operating as usual [2] - Company specializes in the research, design, production, and sales of paper printing and packaging products [2] Group 3: 密尔克卫 - Three shareholders plan to reduce their holdings by a total of up to 2% of the company's shares through block trading [3] - The reduction includes 143.63 million shares, 97.65 million shares, and 75.03 million shares, representing 0.91%, 0.62%, and 0.47% of the total share capital respectively [3] - The reduction period is from June 6, 2025, to September 5, 2025, due to personal funding needs [3] Group 4: 舒泰神 - Subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. has obtained a drug production license from the Jiangsu Provincial Drug Administration [4] - The license allows for the production of therapeutic biological products, specifically for registered declaration use [4] - The license is valid until May 7, 2030, and is not expected to have a significant impact on the company's current performance [4] Group 5: 捷顺科技 - Company won the bid for the "Chongqing Beautiful Sunshine Home and other public rental housing supporting parking space operation project" [5] - The project includes four public rental housing supporting parking lots with a total of 13,335 parking spaces [5] - The minimum guaranteed revenue for the project is quoted at 40.43 million yuan per year, with a total contract amount expected to exceed 100 million yuan [5] Group 6: 综艺股份 - Company signed an investment cooperation intention agreement to acquire control of Jiangsu Jilai Microelectronics Co., Ltd. through cash capital increase or share transfer [6] - Jilai Micro primarily engages in the research, production, and sales of power semiconductor chips and devices [6] - The transaction is expected to constitute a major asset restructuring [6] Group 7: 东山精密 - Subsidiary DSBJ PTE. LTD. plans to acquire 100% equity of French GMD Group for approximately 100 million euros (about 814 million yuan) [7] - The acquisition aims to advance the company's globalization strategy and enhance its market share in the automotive parts sector [7] - The company specializes in the research, production, and sales of electronic circuit products and precision components [7] Group 8: 诺诚健华 - Company reported a net profit of 17.97 million yuan for the first quarter of 2025, a significant turnaround from a loss of 142 million yuan in the same period last year [8] - The first quarter revenue reached 381 million yuan, representing a year-on-year growth of 129.92% [8] - The company focuses on the research, production, and commercialization of innovative drugs [8] Group 9: 凯美特气 - Shareholders plan to reduce their holdings by up to 3% of the company's shares through centralized bidding and/or block trading [9] - The total number of shares to be reduced is 20.86 million [9] - The reduction is due to personal funding needs [9] Group 10: 海创药业 - Controlling shareholder plans to reduce holdings by up to 2% of the company's shares through centralized bidding and block trading [10] - The total number of shares to be reduced is 1.98 million [10] - The reduction is due to personal funding needs [10] Group 11: 高争民爆 - Controlling shareholder plans to reduce holdings by up to 3% of the company's shares through centralized bidding and block trading [11] - The total number of shares to be reduced is 828,000 [11] - The reduction is due to the company's funding needs [11] Group 12: 金埔园林 - Two shareholders plan to reduce their holdings by a total of up to 1.91% of the company's shares [12] - The reductions include 183.93 million shares and 167.73 million shares [12] - The reasons for the reductions are asset optimization and personal funding needs [12] Group 13: 掌趣科技 - The largest shareholder plans to reduce holdings by up to 1% of the company's shares through centralized bidding or block trading [13] - The total number of shares to be reduced is 27.2 million [13] - The reduction is due to personal funding needs [13] Group 14: 美凯龙 - Company announced that its director and general manager has been placed under investigation and detention by the local supervisory committee [14] - Other board members and senior management are performing their duties normally, and daily operations are unaffected [14] - The company specializes in managing and operating self-operated and franchised shopping malls [14] Group 15: 新强联 - Major shareholder plans to reduce holdings by up to 1.89% of the company's shares through centralized bidding and block trading [15] - The total number of shares to be reduced is 717,490 [15] - The reduction is due to operational needs [15] Group 16: 日月明 - Shareholder plans to reduce holdings by up to 1% of the company's shares through centralized bidding [16] - The total number of shares to be reduced is 80,000 [16] - The reduction is due to personal funding needs [16] Group 17: 同有科技 - Major shareholder and vice president plan to reduce their holdings by up to 1.53% of the company's shares [17] - The total number of shares to be reduced is 730,850 [17] - The reduction is due to personal funding needs [17] Group 18: 爱尔眼科 - Subsidiary successfully acquired 60% equity and specific debt of Shenzhen Guangsheng Digital Technology Co., Ltd. for 650 million yuan [18] - The transaction constitutes a related party transaction [18] - The acquired asset will serve as long-term medical premises for the subsidiary [18]

证券代码：688302 证券简称：海创药业 公告编号：2025-028 海创药业股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告日，海创药业股份有限公司（以下简称"公司"）股东，成都盈 创动力创业投资有限公司（以下简称"盈创动力"）持有公司股份 6,215,901 股， 占公司总股本的 6.2777%，其中无限售条件的流通股 6,215,901 股。上述股份为 公司首次公开发行前取得的股份，并已于 2023 年 6 月 15 日解除限售并上市流通。 公司近日收到股东盈创动力发出的《关于减持股份计划的告知函》。因自身 资金需求，盈创动力拟自本公告披露之日起 15 个交易日后的 3 个月内通过集中 竞价、大宗交易方式减持所持有公司股份合计不超过 1,980,310 股，占公司总股 本的 2%。若公司在上述减持计划实施期间发生派发红利、送红股、转增股本、 增发新股或配股等股本除权、除息事项的，则上述减持计划将作相应调整。 依据《上海证 ...

海创药业公告，股东盈创动力计划自公告披露之日起15个交易日后的3个月内，通过集中竞价和大宗交 易方式减持不超过198.03万股，占公司总股本的2%。 ...

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry [6] Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11] - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13] - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 industry indices [2][11] - The year-to-date performance shows a 1.19% increase, ranking 15th among the indices [13] 2. Key Company Announcements - Notable companies such as Kellytai, BGI Genomics, and Dongfang Bio have reported varying financial results, with some showing declines in net profit [21] 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22] - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22] - The report suggests that the innovative drug sector is entering a phase of realization of results, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22] 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%) and Haichuang Pharmaceutical (+25.85%), while the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20]